Posted On: 03/06/2016 7:28:33 PM
Post# of 30066
Add:
ESS for deep partial and full thickness burns - June 6, 2012
http://www.regenicin.com/Investor-Relations/N...20612.html
In the last presentation GC said they should also being hearing back from the FDA on GCMN in a few weeks. Usually takes about 60 days, but they are very busy.
Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi - DECEMBER 29, 2015
http://ir.amarantus.com/press-releases/detail...rphan-drug
ESS for deep partial and full thickness burns - June 6, 2012
http://www.regenicin.com/Investor-Relations/N...20612.html
In the last presentation GC said they should also being hearing back from the FDA on GCMN in a few weeks. Usually takes about 60 days, but they are very busy.
Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi - DECEMBER 29, 2015
http://ir.amarantus.com/press-releases/detail...rphan-drug
Quote:
Orphan Drug Designations awarded to Amarantus
MANF for Retinitis Pigmentosa (USA) - 12/23/2014
MANF for Retinitis Pigmentosa (EU) - 4/29/2015
MANF for Retinal Artery Occlusion - 9/14/2015
Eltoprazine for Parkinson's Disease Levodopa-Induced Dyskinesia - 2/10/2016
(8)
(0)
